ProQR Therapeutics NV (PRQR)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 17, 2025

$2.37

P/E Ratio

N/A

Market Cap

$244.59M

Jan 29, 2024Mar 4, 2024Apr 4, 2024May 9, 2024Jun 12, 2024Jul 16, 2024Aug 19, 2024Sep 24, 2024Oct 29, 2024Dec 2, 2024Jan 20, 2025$0.00$10.00
  • 9310
Description

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

Metrics

Overview

  • HQLeiden, ZH
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerPRQR
  • Price$2.37+3.04%

Trading Information

  • Market cap$244.59M
  • Float71.97%
  • Average Daily Volume (1m)292,808
  • Average Daily Volume (3m)621,022
  • EPS-$0.32

Company

  • Revenue$19.37M
  • Rev growth (1yr)183.27%
  • Net income-$8.91M
  • Gross margin82.10%
  • EBITDA margin-212.49%
  • EBITDA-$8.97M
  • EV$66.50M
  • EV/Revenue3.43
  • P/EN/A
  • P/S9.99
  • P/B6.94
Documents